Skip to content
Subscriber Only

Research Firm for Pfizer, Novartis Morphs Into Low-Cost Rival

  • TrialSpark expands from clinical trials into developing drugs
  • Company raised $156 million, is valued at more than $1 billion
Ben Liu
Ben LiuPhotographer: Yuliya Nar/TrialSpark

A startup known for conducting research on behalf of pharmaceutical companies like Pfizer Inc. and Novartis AG now aims to compete with them by making medications itself.

New York-based TrialSpark Inc. will fund its move into drug development with a $156 million financing round that closed earlier this year and values the company at more than $1 billion. That money will be used largely to buy new drug candidates, as well as for hiring.